| Literature DB >> 12023935 |
Akane Ishihara1, Akio Kanatani, Megumu Okada, Masayasu Hidaka, Takeshi Tanaka, Satoshi Mashiko, Akira Gomori, Tetsuya Kanno, Mikiko Hata, Maki Kanesaka, Yushin Tominaga, Naga-aki Sato, Masahiko Kobayashi, Takashi Murai, Keiko Watanabe, Yasuyuki Ishii, Takahiro Fukuroda, Takehiro Fukami, Masaki Ihara.
Abstract
1. An experiment was conducted to examine whether a potent, orally active and highly selective neuropeptide Y Y1 receptor antagonist attenuates hyperphagia and obesity in genetically obese Zucker fatty rats. 2. Oral administration of the Y1 antagonist (30 and 100 mg x kg(-1), once daily for 2 weeks) significantly suppressed the daily food intake and body weight gain in Zucker fatty rats accompanied with a reduction of fat cell size and plasma corticosterone levels. 3. Despite the fact that food intake was gradually returned to near the control level, the body weight of the treated animals remained significantly less when compared to that of the controls for the duration of the treatment. 4. These results suggest that the Y1 receptor, at least in part, participate in pathophysiological feeding and/or fat accumulation observed in Zucker fatty rats. Y1 antagonists might be useful for the treatment of obesity.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12023935 PMCID: PMC1573355 DOI: 10.1038/sj.bjp.0704696
Source DB: PubMed Journal: Br J Pharmacol ISSN: 0007-1188 Impact factor: 8.739